Trial Profile
Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Acoustic neuroma; Haemangioblastoma; Meningioma; Neurilemmoma; Neurofibromatosis 1; Neurofibromatosis 2
- Focus Therapeutic Use
- 04 Jan 2021 Status changed from active, no longer recruiting to completed.
- 11 Apr 2018 Planned End Date changed from 1 Jul 2018 to 1 Jul 2020.
- 11 Apr 2018 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2019.